Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society
Zurich, Switzerland: 17 September 2018 – Sequana Medical AG, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today positive findings from its Retrospective Malignant Ascites Study.
The study retrospectively evaluated 17 patients with malignant ascites that had been implanted with the alfapump® in centres across Europe. The study demonstrated that the alfapump® was effective in treating palliative patients with malignant ascites and improving their quality of life.
The findings of the study were presented by Principal Investigator, Christina Fotopoulou MD, PhD, Imperial College London at the 17th Biennial Meeting of the International Gynecologic Cancer Society that was held from 14-16 September in Kyoto, Japan.
More info on Sequana’s website.